Compugen (CGEN)
Builds cancer immunotherapies from computationally predicted drug targets.
$2.65
Pre-market+0.03 (+1.00%)
At close$2.63(+1.35%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 33 | 3 | 7 | 17 | 1 | 2 | 1 | 2 | 67 | 2 | 3 |
| Cost of revenue | 0 | 2 | 2 | 2 | 4 | 1 | 2 | 2 | 2 | 4 | 2 | 3 |
| Gross profit | 0 | 31 | 0 | 5 | 14 | 1 | 0 | 0 | 0 | 64 | 0 | 0 |
| 11 | 13 | 9 | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 9 | 9 | |
| Research & development | 8 | 11 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 6 |
| 2 | 3 | 3 | 2 | 3 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Operating income | −11 | 18 | −8 | −3 | 4 | −7 | −8 | −8 | −8 | 56 | −9 | −9 |
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | |
| Interest income | 1 | — | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 2 |
| Other non-operating income | 0 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −1 | −2 |
| Income before tax | −10 | 19 | −7 | −2 | 6 | −6 | −7 | −7 | −7 | 57 | −8 | −7 |
| Income tax expense | 0 | 9 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −10 | 10 | −7 | −2 | 1 | −6 | −7 | −7 | −7 | 57 | −8 | −7 |
| Net income | −10 | 10 | −7 | −2 | 1 | −6 | −7 | −7 | −7 | 57 | −8 | −7 |
| EPS, basic | −$0.11 | $0.11 | −$0.08 | −$0.02 | $0.01 | −$0.07 | −$0.08 | −$0.08 | −$0.07 | $0.60 | −$0.08 | −$0.07 |
| EPS, diluted | −$0.11 | $0.11 | −$0.08 | −$0.02 | $0.01 | −$0.07 | −$0.08 | −$0.08 | −$0.07 | $0.60 | −$0.08 | −$0.07 |
| Weighted average shares, basic | 88 | 88 | 90 | 90 | 90 | 90 | 92 | 94 | 94 | 94 | 95 | 95 |
| Weighted average shares, diluted | 88 | 88 | 90 | 90 | 90 | 90 | 92 | 94 | 94 | 95 | 95 | 95 |
| EBITDA | −11 | 19 | −7 | −2 | 6 | −6 | −7 | −7 | −7 | 57 | −8 | −7 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −11 | 19 | −7 | −2 | 6 | −6 | −7 | −7 | −7 | 57 | −8 | −7 |